Advantage Alpha Capital Partners LP Halozyme Therapeutics, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 14,738 shares of HALO stock, worth $704,329. This represents 0.2% of its overall portfolio holdings.
Number of Shares
14,738
Previous 24,506
39.86%
Holding current value
$704,329
Previous $1.28 Million
34.29%
% of portfolio
0.2%
Previous 0.29%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
544Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$842 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$616 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$317 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$194 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$163 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.66B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...